SCM
NVCT icon

Sterling Capital Management’s Nuvectis Pharma NVCT Stock Holding History

Sterling Capital Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1K Sell
60
-40
-40% -$448 ﹤0.01% 3108
2026
Q1 		$773 Buy
100
+16
+19% +$137 ﹤0.01% 3113
2025
Q4 		$634 Buy
84
+53
+171% +$346 ﹤0.01% 3175
2025
Q3 		$187 Hold
31
– – ﹤0.01% 3213
2025
Q2 		$232 Buy
+31
New +$281 ﹤0.01% 3227

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Sterling Capital Management's NVCT Position: Q2 2026 in Review

Sterling Capital Management reduced its Nuvectis Pharma (NVCT) stake by 40% in Q2 2026, selling an estimated $448 and leaving 60 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3108.

Sterling Capital Management first reported a position in NVCT in Q2 2025 and has held it in 5 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Sterling Capital Management held 60 shares of Nuvectis Pharma worth $1.1K as of Q2 2026.
  • Sterling Capital Management sold 40 Nuvectis Pharma shares in Q2 2026, an estimated $448.
  • Nuvectis Pharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3108 holding.
  • Sterling Capital Management first reported a position in Nuvectis Pharma in Q2 2025 and has held it in 5 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.